progress
multifoc
leukoencephalopathi
pml
sever
debilit
often
fatal
demyelin
diseas
central
nervou
system
cn
immunosuppress
individu
caus
jc
polyomaviru
jcv
ubiquit
human
pathogen
demyelin
result
lytic
infect
oligodendrocyt
whose
clearanc
impair
set
depress
jcvspecif
cellmedi
cn
surveil
although
mutat
viral
capsid
genom
rearrang
viral
noncod
region
appear
set
stage
pml
immunosuppress
popul
mechan
demyelin
cn
antivir
immun
poorli
understood
larg
part
due
absenc
tractabl
anim
model
mimic
pml
neuropatholog
human
earli
studi
use
mous
polyomaviru
mpyv
celldefici
mice
demonstr
product
viral
replic
cn
demyelin
howev
find
confound
spinal
cord
compress
virusinduc
vertebr
bone
tumor
review
current
literatur
regard
anim
model
pml
focus
current
trend
antivir
cell
immun
nonlymphoid
organ
includ
cn
advanc
understand
polyomaviru
lifecycl
viral
host
determin
persist
infect
cellmedi
immun
viral
infect
cn
warrant
revisit
polyomaviru
cn
infect
mous
bona
fide
anim
model
jcvpml
human
jc
polyomaviru
jcv
persist
silent
healthi
adult
popul
recent
evid
suggest
even
higher
preval
seroepidemiolog
studi
indic
individu
first
expos
jcv
late
adolesc
base
detect
jcv
tonsil
sewag
viru
like
acquir
via
respiratori
andor
fecalor
transmiss
rout
jcv
discov
etiolog
agent
progress
multifoc
leukoencephalopathi
pml
lifethreaten
demyelin
diseas
central
nervou
system
cn
result
lytic
infect
oligodendrocyt
pml
first
describ
patient
chronic
lymphocyt
leukemia
hodgkin
lymphoma
sinc
diagnos
individu
immunosuppress
varieti
hematolog
malign
advent
highli
activ
antiretrovir
therapi
haart
approxim
individu
afflict
hivaid
develop
pml
pml
becam
regard
aidsassoci
diseas
profound
immunosuppress
howev
essenti
prelud
pml
pml
seen
hivneg
individu
occult
minim
immunosuppress
caus
old
age
chronic
liver
kidney
diseas
untreat
dermatomyos
idiopath
lymphopenia
effect
antijcv
agent
current
avail
prognosi
pml
poor
recent
pml
emerg
patient
receiv
humor
immunomodulatori
agent
autoimmun
diseas
inflammatori
disord
trilog
articl
new
england
journal
medicin
describ
pml
patient
relapsingremit
multipl
sclerosi
ms
crohn
diseas
given
monoclon
antibodi
natalizumab
tysabri
recent
studi
report
risk
pml
increas
durat
natalizumab
therapi
high
case
per
patient
ms
patient
seroposit
jcv
month
monthli
infus
therapi
histori
immunosuppress
ms
treatment
regimen
design
reduc
autoreact
immun
respons
natalizumab
human
antibodi
integrin
complex
integrin
form
late
surfac
activ
cell
enabl
cell
traffic
site
infectioninflamm
mucos
tissu
respect
requir
cell
extravas
mediat
leukocyt
arrest
activ
vascular
endothelium
express
ligand
vascular
cell
adhes
molecul
ligand
mucos
addressin
cell
adhes
molecul
support
hypothesi
natalizumabmedi
blockad
impair
cn
immun
surveil
earli
studi
show
cohort
ms
patient
receiv
natalizumab
decreas
count
cell
b
cell
plasma
cell
csf
compar
untreat
ms
patient
patient
neurolog
diseas
patient
avail
sixmonth
followup
cessat
natalizumab
therapi
one
decreas
count
lymphocyt
popul
one
except
patient
modest
elev
cell
count
coincid
clinic
ms
replas
monoclon
antibodybas
immunomodulatori
therapi
includ
efalizumab
sever
plaqu
psoriasi
rituximab
b
cell
lymphoma
shown
put
patient
risk
pml
risk
efalizumab
taken
market
despit
efficaci
reduc
reject
kidney
transplant
recipi
develop
intens
steroidavoid
immunosuppress
agent
transplant
medicin
concern
incid
pml
may
also
rise
patient
popul
happen
bk
viru
bkv
associ
nephropathi
recent
evid
suggest
inadequ
cellmedi
surveil
jcvinfect
cn
glial
cell
common
mechan
among
immunosuppress
regimen
confer
suscept
pml
discuss
natalizumab
interfer
traffick
circul
effector
cell
cn
rheumatoid
arthriti
patient
receiv
rituximab
show
mark
cell
deplet
particularli
cell
compart
associ
clinic
respons
b
celldeplet
therapi
rituximab
may
affect
cell
respons
deplet
b
cellderiv
cytokineschemokin
elimin
b
cell
capac
profession
antigenpres
cell
activ
cell
possibl
limit
avail
immun
complex
crosspres
antigen
cell
dendrit
cell
immun
reconstitut
haart
aid
plasma
exchang
monoclon
antibodi
therapi
recommend
treatment
option
pml
regimen
predispos
patient
rapid
robust
often
fatal
influx
circul
leukocyt
cn
term
immun
reconstitut
inflammatori
syndrom
iri
paradox
treatment
accentu
pml
lesion
caus
relaps
autoimmun
diseas
case
organ
transplant
recipi
lead
graft
reject
addit
underli
depress
alter
immun
function
viral
determin
may
also
increas
pml
risk
andor
diseas
sever
mutat
result
singl
amino
acid
substitut
host
cell
receptor
bind
domain
viral
capsid
protein
rearrangementsdelet
noncod
control
region
nccr
found
jcv
sequenc
cerebrospin
fluid
csf
pml
patient
mutat
may
constitut
necessari
viral
determin
pml
underli
sharp
discrep
high
preval
jcv
infect
low
incid
pml
recent
work
demonstr
rearrang
nccr
confer
increas
earli
viral
gene
express
dna
replic
capabl
glial
cell
import
role
jcv
capsid
protein
cn
tropism
support
evid
hybrid
viru
contain
earli
gene
monkey
polyomaviru
late
gene
pmljcv
strain
acquir
restrict
host
rang
jcv
ie
abil
infect
human
fetal
glial
cell
monkey
cell
hemagglutin
human
type
red
blood
cell
use
jcv
viruslik
particl
vlp
suggest
pmlassoci
jcv
capsid
mutat
alter
viral
tropism
retain
virion
bind
specif
cn
glial
cell
noncn
cell
type
differ
wild
type
vlp
glycan
specif
howev
pseudovirus
mutat
fail
transduc
glial
cell
rais
possibl
csf
variant
noninfecti
whether
variant
confer
neurovirul
jcv
whether
jcv
acquir
mutat
peripheri
entri
brain
remain
determin
sever
line
evid
suggest
humor
immun
select
mutant
polyomavirus
exposur
librari
variant
neutral
monoclon
antibodi
select
virus
mutat
solventexpos
loop
resist
neutral
antibodi
bkv
serotyp
shown
vari
level
crossrecognit
neutral
antibodi
gener
vlp
immun
interestingli
bkv
isol
kidney
transplant
patient
nephropathi
viremia
also
high
frequenc
substitut
find
rais
possibl
neutral
antibodi
respons
select
variant
polyomavirus
mutat
enabl
escap
antivir
humor
immun
whether
cell
immunosuppressionmodul
favor
neutral
antibodydriven
select
polyomaviru
escap
variant
unknown
progress
understand
pathogenesi
jcvinduc
pml
develop
effect
therapeut
approach
handicap
low
number
pml
case
inadequ
understand
risk
factor
three
broad
risk
factor
describ
date
natalizumabtr
ms
individu
jcv
seroposit
prior
immunosuppress
therapi
heterogen
among
pml
patient
eg
differ
immunosuppress
regimen
hla
type
age
gender
addit
obstacl
includ
consist
patient
complianc
clinic
studi
underreport
underrecognit
diseas
rapid
diseas
progress
follow
diagnosi
jcv
replic
human
limit
understand
pathogenesi
pml
immun
mechan
need
keep
persist
polyomaviru
infect
check
studi
evolut
pml
patholog
rather
endpoint
diseas
pml
diagnos
essenti
identifi
factor
predispos
small
fraction
immunosuppress
individu
receiv
immunomodulatori
therapi
pml
anim
model
polyomavirusinduc
cn
diseas
mimic
patholog
hallmark
pml
would
circumv
obstacl
enabl
us
address
import
unansw
question
includ
facet
innat
adapt
immun
control
jcv
infect
brain
immunosuppressionimmunomodul
interfer
control
circumst
antivir
immun
surveil
cn
may
prove
patholog
rather
protect
pathogenesi
pml
vari
differ
immunomodulatori
regimen
howwhen
jcv
traffic
cn
pmlassoci
viral
mutat
acquir
confer
neurotropismneurovirul
jcv
mutat
result
immun
selectionevas
individu
treat
humor
immun
modulatori
agent
suscept
jcv
enceph
encephalitid
caus
persist
microbi
pathogen
eg
toxoplasmosi
tractabl
small
anim
model
cn
infect
natur
host
polyomaviru
provid
insight
pml
risk
factor
mechan
diseas
provid
preclin
model
evalu
candid
antivir
agent
review
current
literatur
cellmedi
control
viral
infect
nonlymphoid
organ
includ
cn
describ
potenti
mechan
dampen
cell
function
set
persist
cn
infect
advoc
applic
mous
polyomaviru
mpyv
model
understand
immun
control
polyomaviru
infect
cn
effect
immun
virus
typic
depend
cell
abil
directli
target
kill
viral
infect
cell
accordingli
presenc
detect
jcvspecif
cell
peripher
blood
correl
improv
prognosi
surviv
pml
patient
wherea
antijcv
humor
respons
hiv
patient
detect
level
jcvspecif
cell
coincid
higher
number
cell
presenc
peripher
blood
posit
correl
pml
surviv
domin
cell
epitop
found
jcvseroposit
individu
direct
determin
correspond
residu
former
domin
specif
stain
hlaa
tetram
show
jcvspecif
cell
effectormemori
phenotyp
lo
hi
found
pbmc
healthi
individu
perhap
contribut
overal
low
incid
pml
inde
measur
earli
pml
diagnosi
presenc
jcvspecif
pbmc
predict
control
pml
absenc
cell
predict
activ
pml
progress
hiv
pml
patient
cell
found
infiltr
brain
coloc
infect
oligodendrocyt
edg
pml
lesion
cell
receptor
ligand
mhc
ii
upregul
taken
togeth
find
suggest
jcv
infect
predominantli
control
cell
studi
human
jcvspecif
cell
respons
predominantli
base
analysi
pbmc
jcvspecif
cell
isol
healthi
individu
pml
patient
jcvspecif
cell
gener
subject
extend
expans
select
tissu
cultur
may
obscur
conclus
regard
vivo
phenotyp
function
highlight
earli
studi
show
longterm
vitro
cell
prolifer
profoundli
underestim
frequenc
antigenspecif
cell
vivo
although
develop
mhc
tetram
detect
jcvspecif
cell
improv
quantif
cell
low
incid
pml
coupl
defin
hla
class
irestrict
jcv
epitop
limit
direct
analys
jcvspecif
cell
pml
patient
addit
analysi
cnsinfiltr
cell
hamper
pml
brain
lesion
show
minim
inflamm
may
due
patient
immunosuppress
state
late
stage
diseas
time
diagnosi
one
studi
analyz
cnsinfiltr
jcvspecif
cell
directli
ex
vivo
flow
cytometri
use
fresh
brain
biopsi
natalizumabtr
ms
patient
pronounc
cell
infiltr
secondari
iri
examin
immun
surveil
prior
diagnosi
pml
limit
csf
sampl
necessarili
reflect
immun
infiltr
brain
parenchyma
given
limit
data
avail
regard
type
function
locat
cellular
infiltr
brain
parenchyma
littl
known
statu
immun
surveil
cn
jcvinfect
cell
prior
pml
progress
insight
evolut
mainten
jcvspecif
cell
respons
human
cn
would
greatli
benefit
mous
model
polyomaviru
cn
infect
use
anim
model
would
provid
insight
kinet
antipolyomaviru
immun
surveil
cn
immun
suppress
alter
surveil
incid
neuropatholog
inbr
strain
mice
simplifi
identif
viral
peptid
cell
epitop
essenti
monitor
magnitud
phenotyp
function
virusspecif
cell
incis
identif
determin
effect
cn
immun
respons
achiev
use
transgen
mice
mice
target
genet
delet
antibodymedi
blockad
key
interact
delet
specif
cell
type
mous
model
viral
infect
optim
pathogen
dose
time
postinfect
yield
higher
number
immun
cell
studi
directli
ex
vivo
furthermor
immun
cell
isol
mous
tissu
provid
insight
potenti
differentiationregul
cell
situ
cn
studi
use
mous
model
underpin
newfound
appreci
circul
cell
phenotyp
function
distinct
resid
nonlymphoid
tissu
memori
cell
heterogen
phenotyp
differenti
function
paramet
link
migrat
pattern
anatom
locat
sinc
origin
descript
nonlymphoid
organhom
effector
memori
versu
lymphoid
organhom
central
memori
popul
evid
quickli
accumul
memori
cell
heterogen
integr
tissu
resid
ie
depend
tissu
local
memori
cell
vari
express
chemokin
receptor
adhes
molecul
effector
capabl
effectormemori
cell
thought
compris
circul
noncircul
subset
latter
tissu
resid
memori
cell
rm
cell
distinguish
circul
effectormemori
cell
upregul
granzym
b
canon
indic
tcr
activ
cytotox
effector
capabl
respect
cell
surfac
express
e
integrin
e
complex
bind
ecadherin
express
implic
role
integrin
cell
retent
epithelium
recent
work
show
variabl
express
rm
cell
differ
tissu
suggest
per
se
signatur
rm
cell
marker
wwwfrontiersinorg
directli
antagon
express
receptor
express
cell
enabl
egress
peripher
lymphoid
organ
downregul
essenti
retent
cell
tissu
key
mediat
express
activ
cell
skin
intestin
mucosa
well
cn
may
also
involv
upregul
rm
cell
persist
longterm
skin
mucos
site
respiratori
tract
femal
reproduct
tract
gut
intestin
least
mainten
rm
cell
antigenindepend
rapidli
expand
bodi
literatur
demonstr
rm
cell
contribut
host
defens
bacteri
viral
reencount
mucos
epiderm
site
antivir
cell
also
establish
resid
cn
appear
differ
requir
function
surviv
compar
extracn
nonlymphoid
tissu
intracrani
ic
inocul
mice
vesicular
stomat
viru
vsv
acut
infect
pathogen
result
progress
accumul
brain
hi
granzym
b
hi
virusspecif
rm
cell
whose
mainten
antigenindepend
requir
differ
viru
interact
host
eg
level
antigen
persist
cytopathicnoncytopath
cell
fate
host
cell
tropism
undoubtedli
influenc
establish
mainten
function
cnsresid
memori
cell
immunosurveil
efficaci
infect
cell
presenc
cnsinfiltr
cell
circumscrib
demyelin
lesion
associ
improv
clinic
outcom
hivaidsrel
pml
patient
associ
extend
explain
develop
pml
ms
patient
receiv
natalizumab
ms
progress
character
two
distinct
phase
primari
relapsingremit
stage
repetit
acut
infiltr
brain
myelinreact
cell
occur
inflamm
resolv
secondari
progress
phase
littl
inflamm
observ
lesion
demyelin
function
disabl
worsen
natalizumab
act
exclud
circul
activ
cell
cn
possibl
jcvspecif
cell
infiltr
brain
natalizumabtr
ms
patient
activ
jcv
replic
ms
difficult
diseas
diagnos
patient
like
experi
acut
autoreact
inflamm
prior
initi
natalizumab
therapi
myelinreact
inflamm
may
render
bloodbrain
barrier
permeabl
jcv
free
virion
via
infect
cell
discuss
well
jcvreactiv
cell
connect
merit
note
natalizumab
typic
firstlin
treatment
option
ms
jcv
infect
brain
subsequ
cell
infiltr
occur
prior
administr
natalizumab
therapi
cnsinfiltr
jcvspecif
cell
would
affect
could
potenti
establish
resid
memori
popul
base
data
variou
anim
model
tissu
resid
memori
cell
context
persist
infect
cn
function
jcvspecif
rm
cell
might
surviv
longterm
driven
dysfunct
delet
former
case
jcvspecif
rm
cell
would
protect
wherea
latter
situat
exhaust
rm
cell
may
predomin
fail
limit
number
infect
oligodendrocyt
natalizumab
would
prevent
replenish
cnsinfiltr
jcvspecif
cell
circul
blood
result
defici
cellmedi
immun
surveil
infect
glial
cell
altern
scenario
may
help
explain
rariti
pml
even
immunocompromis
individu
know
longev
function
rm
cell
cn
would
readili
studi
use
mous
model
polyomaviru
cn
infect
may
help
explain
increas
risk
pml
longterm
natalizumab
therapi
brain
wide
consid
immuneprivileg
organ
recent
immun
privileg
thought
result
complet
exclus
immun
effector
cell
howev
healthi
immuneprivileg
site
actual
subject
activ
immun
surveil
requir
function
immun
effector
cell
tightli
manag
protect
vital
nonrenew
tissu
regul
cell
immun
respons
typic
depend
balanc
activ
inhibitori
signal
molecul
express
activ
cell
counter
activ
signal
cascad
initi
tcr
ligat
express
significantli
elev
jcvspecif
cell
peripher
blood
pml
patient
induc
tcr
signal
express
maintain
set
persist
antigen
stimul
chronic
viral
infect
cancer
autoimmun
bind
two
ligand
also
call
differ
express
pattern
broadli
express
hematopoiet
parenchym
cell
induc
express
dc
macrophag
recent
work
indic
variabl
level
signal
translat
differenti
dampen
cell
function
low
level
inhibit
product
cell
prolifer
higher
level
inhibit
cytotox
product
sustain
high
express
set
chronic
virem
infect
mediat
exhaust
virusspecif
cell
although
regul
cell
intens
investig
system
persist
viral
infect
surprisingli
littl
known
role
viral
enceph
mous
cytomegaloviru
enceph
brainloc
cell
express
activ
microglia
astrocyt
express
ligand
blockad
microgliaastrocyt
cell
cocultur
increas
product
cell
infiltr
cn
mice
persist
infect
gliatrop
mous
jhm
coronaviru
also
hi
receptor
signal
oligodendrocyt
induc
express
turn
limit
effector
activ
hi
jhmspecif
cell
engag
hi
cell
oligodendrocyt
prevent
cellmedi
axon
bystand
damag
cost
negat
viral
clearanc
interestingli
cn
infect
vsv
neurotrop
nondemyelin
pathogen
associ
robust
virusspecif
cell
brain
infiltr
cell
lack
express
elev
cell
pml
patient
studi
rais
possibl
upregul
properti
cell
respond
gliatrop
viral
infect
data
line
concept
inhibit
frontier
immunolog
multipl
sclerosi
neuroimmunolog
cellmedi
immunopatholog
demyelin
concept
support
studi
document
protect
role
experiment
autoimmun
encephalomyel
eae
mous
model
ms
persist
polyomaviru
infect
establish
lowlevel
antigen
setpoint
upregul
polyomavirusspecif
cell
unexpect
suggest
sustain
strong
tcr
signal
may
essenti
express
brain
hivposit
individu
express
higher
cell
csf
blood
despit
viral
rna
level
lower
csf
certain
common
cytokin
type
ifn
shown
induc
maintain
express
tcractiv
cell
type
type
ii
ifn
upregul
regard
mpyv
transcript
shown
elev
brain
mice
given
mpyv
ic
rais
possibl
polyomavirusinduc
proinflammatori
environ
cn
could
complement
lowintermitt
tcr
engag
upregul
antivir
rm
cell
brain
polyomaviru
cn
infect
anim
model
would
enabl
investig
mechan
upregul
brainresid
virusspecif
cell
function
role
express
cell
cn
tractabl
anim
model
pml
requir
suffici
similar
hallmark
diseas
human
includ
cell
target
viral
replic
mechan
immun
control
associ
risk
factor
neuropatholog
recent
howev
attempt
model
pml
mice
util
etiolog
agent
pml
jcv
handicap
tight
speci
specif
polyomavirida
lack
viral
dna
polymeras
polyomavirus
reli
host
cell
dna
polymeras
apparatu
replic
genom
thu
devis
strategi
overrid
cell
cycl
checkpoint
speci
restrict
polyomavirus
control
level
bind
host
cell
dna
polymeras
complex
viral
origin
replic
molecular
interact
reflect
coevolut
polyomavirida
famili
member
particular
vertebr
speci
nonproduct
infect
polyomavirus
result
integr
viral
genom
host
chromosom
dna
result
tumor
format
accordingli
experi
involv
ic
inocul
nonhuman
primat
mice
jcv
result
nonproduct
infect
develop
astrocytoma
glioblastoma
pmllike
diseas
transgen
mice
contain
earli
region
jcv
cell
predominantli
express
antigen
oligodendrocyt
exhibit
dysmyelin
phenotyp
recapitul
demyelin
associ
jcv
enceph
human
find
larg
obviat
use
jcv
infect
unmanipul
mice
model
pml
partial
preserv
speci
specif
jcv
infect
anim
host
attempt
made
use
jcv
human
mous
model
low
level
jcv
dna
detect
urin
blood
jcvinfect
mice
reconstitut
human
fetal
bone
marrow
thymu
liver
low
number
cell
absenc
human
cn
tissu
provid
cellular
target
jcv
replic
system
recapitul
pml
obstacl
recent
overcom
goldman
colleagu
creat
human
glial
chimer
mice
engraft
human
bipotenti
oligodendrocyteastrocyt
progenitor
cell
congenit
hypomyelin
mbp
shishi
neonat
mice
result
effici
colon
mous
brain
human
astrocyt
oligodendrocyt
myelin
use
human
glial
chimer
mice
kondo
et
al
recent
report
intracerebr
deliveri
jcv
result
earli
widespread
product
infect
engraft
human
astrocyt
focal
demyelin
gliosi
rare
oligodendrocyt
infect
earli
postinfect
late
timepoint
larg
number
antigen
oligodendrocyt
detect
find
rais
provoc
possibl
demyelin
may
larg
part
account
defici
trophic
support
oligodendrocyt
result
death
product
infect
astrocyt
rather
elimin
oligodendrocyt
lytic
jcv
infect
anoth
notabl
find
studi
rapid
emerg
sizeabl
number
genom
mutat
least
two
previous
seen
jcv
isol
pml
patient
thu
astrocyt
may
major
site
emerg
neurovirul
variant
virus
chimer
mous
model
repres
import
advanc
toward
understand
mechan
pathogenesi
demyelin
howev
infect
human
gliaengraft
mice
provid
insight
role
jcvspecif
immun
respons
cn
major
unresolv
question
mode
transit
jcv
cn
ie
free
viru
andor
via
infect
trojan
hors
cell
deep
sequenc
jcv
nccr
match
urin
plasma
csf
sampl
pml
patient
provid
strong
support
hematogen
rout
viral
dissemin
conclus
line
earlier
evid
mutat
detect
blood
csf
urin
pml
patient
human
brain
microvascular
endotheli
cell
demonstr
permiss
jcv
infect
find
support
possibl
jcv
may
cross
bloodbrain
barrier
infect
endotheli
cell
favor
cellbas
bloodtobrain
carriag
earli
studi
report
detect
jcv
bkv
dna
peripher
blood
leukocyt
healthi
adult
subsequ
work
focus
attent
b
cell
andor
hematopoiet
progenitor
cell
hpc
candid
vehicl
convey
jcv
cn
jcv
dna
well
express
antigen
observ
hpc
cell
line
b
cell
line
primari
b
cell
infect
vitro
highdos
viru
inocula
rare
jcv
dna
b
cell
detect
pbmc
pml
patient
addit
rearrang
nccr
contain
multipl
bind
site
spib
transcript
factor
enhanc
jcv
replic
express
b
cell
hpc
glial
cell
review
ref
notabl
gene
express
unfraction
blood
sort
b
cell
hpc
ms
patient
receiv
natalizumab
reveal
upregul
gene
involv
b
cell
activ
differenti
includ
spib
find
wwwfrontiersinorg
line
propos
upregul
specif
transcript
factor
bind
jcv
nccr
underli
resurg
jcv
replic
natalizumabtr
individu
b
cell
endow
recombin
apparatu
enabl
v
j
recombin
immunoglobulin
gene
segment
b
cell
also
propos
provid
environ
conduc
jcv
genom
recombin
andor
rearrang
despit
absenc
ragdepend
recombin
signal
sequenc
motif
jcv
genom
whether
b
cell
truli
capabl
support
jcv
replic
remain
demonstr
particularli
light
recent
data
suggest
b
cell
may
carri
intact
input
jcv
virion
transfer
suscept
glial
cell
antibodymedi
blockad
mice
nonhuman
primat
associ
elev
circul
cell
observ
recapitul
natalizumabtr
ms
patient
human
natalizumab
also
report
mobil
cell
preb
cell
b
cell
circul
observ
give
addit
impetu
valu
immunocompet
mous
model
pml
defin
cellular
vehicl
jcv
transport
brain
parenchyma
statu
jcv
replic
cell
investig
possibl
role
blockad
promot
jcv
spread
cn
mous
polyomaviru
found
member
polyomavirida
famili
structur
genom
similar
jcv
bkv
polyomavirus
polyomavirus
consist
doublestrand
coval
close
dna
genom
encapsid
nonenvelop
icosahedr
shell
compos
pentamer
capsom
genom
polyomavirus
nccr
contain
origin
replic
bidirect
promot
separ
genom
earli
late
gene
respect
onset
viral
dna
synthesi
earli
region
encod
nonstructur
small
larg
antigen
late
region
encod
viral
capsid
protein
unlik
jcv
mpyv
genom
encod
agnoprotein
late
region
contain
addit
earli
region
sequenc
encod
nonstructur
middl
antigen
mediat
cellular
transform
tumor
induct
mous
polyomaviru
also
resembl
bkv
jcv
regard
infect
interact
immun
system
epidemiolog
survey
wild
mice
show
mpyv
like
human
counterpart
wide
preval
harmless
pathogen
natur
host
reservoir
mpyv
infect
varieti
epitheli
mesenchym
cell
macrophag
dc
lymphocyt
neuroectoderm
lineag
cell
state
nonpermiss
mpyv
replic
evid
host
cell
rang
restrict
lack
describ
pmljcv
variant
strain
mpyv
carri
singl
amino
acid
differ
differ
glycan
specif
turn
alter
tissu
tropism
pathogenesi
similar
report
longterm
persist
jcv
bkv
dna
varieti
human
tissu
mpyv
dna
detect
multipl
organ
includ
cn
kidney
bone
marrow
month
acut
infect
immunodefici
immunocompet
mice
declin
immunolog
statu
set
stage
viral
reactiv
human
mous
polyomaviru
infect
elicit
potent
neutral
antibodi
respons
direct
toward
inhibit
capsid
bind
sialyat
glycolipid
glycoprotein
receptor
host
cell
mpyv
persist
infect
mice
presenc
virusneutr
ab
similarli
neutral
ab
jcv
typic
present
individu
confer
protect
pml
neither
human
mous
polyomavirus
caus
overt
diseas
immunocompet
adult
host
immunosuppress
provid
opportun
human
mous
polyomavirus
induc
varieti
diseas
process
mpyvinduc
reject
mous
renal
allograft
use
understand
immunosuppress
alter
evolut
polyomavirusassoci
nephropathi
immun
respons
polyomaviru
infect
contribut
allograft
injuri
mous
polyomaviru
replic
caus
diseas
cn
primari
glial
cell
deriv
mous
corpu
callosum
show
type
astrocyt
neither
type
astrocyt
oligodendrocyt
infect
mpyv
case
vivo
infect
congenit
athym
mice
mpyv
result
wast
diseas
spinal
cord
demyelin
consequ
infect
oligodendrocyt
demyelin
lesion
observ
euthym
mice
emphas
role
immun
suppress
diseas
progress
infect
nude
mice
eventu
develop
hind
limb
paralysi
attribut
vertebr
bone
tumor
rather
pmllike
diseas
earli
studi
mice
infect
natur
rout
transmiss
via
contamin
neighbor
mous
room
studi
involv
ic
inocul
adult
nude
mice
lid
strain
mpyv
caus
fatal
kidney
brain
hemorrhag
newborn
mice
paralysi
vertebr
tumor
develop
absenc
demyelin
public
larg
respons
de
facto
moratorium
use
mpyv
cn
infect
model
pml
interestingli
molecular
model
show
valinetoalanin
substitut
amino
acid
lid
ortholog
jcv
serin
phenylalaninetyrosin
mutat
among
frequent
mutat
detect
gene
jcv
isol
pml
patient
although
mpyvmous
model
cn
diseas
reproduc
aspect
jcvpml
patholog
human
signific
aspect
mous
model
fulli
recapitul
human
diseas
new
evid
exist
tissuespecif
protect
antivir
cell
recent
work
laboratori
use
ic
inocul
mpyv
tumorresist
mice
suggest
mpyv
may
prove
import
anim
model
polyomavirusinduc
cn
demyelin
progress
multifoc
leukoencephalopathi
rare
complic
immunosuppress
caus
infect
cn
jc
viru
highli
ubiquit
silent
human
pathogen
healthi
individu
wide
discord
viru
preval
diseas
incid
appear
stem
coalesc
multipl
predispos
factor
includ
viral
determin
alter
host
cell
tropism
host
immun
determin
affect
cn
frontier
immunolog
multipl
sclerosi
neuroimmunolog
surveil
infect
glial
cell
variabl
underli
immunosuppress
diseasetreat
regimen
lack
tractabl
anim
model
due
tight
speci
specif
polyomavirida
stymi
effort
determin
contribut
factor
pml
pathogenesi
review
literatur
describ
previou
attempt
develop
anim
model
pml
propos
use
mous
polyomaviru
studi
interplay
host
immun
respons
infect
brain
signific
research
use
peripher
blood
mononuclear
cell
autopsybiopsi
tissu
pml
patient
implic
role
jcvspecif
cell
respons
diseas
outcom
mpyv
enceph
model
provid
insight
mechan
jcvinduc
demyelin
evolut
protectivepatholog
immun
respons
jcv
cn
infect
situ
well
provid
preclin
platform
evalu
strategi
prevent
control
pml
